The ICMR funded cancer study, published in the prestigious peer-reviewed Molecular Therapy Oncology (May/June, 2025), demonstrates CAR-T therapy, which uses patient’s own T cells to fight cancer, can be safely manufactured and infused at point of care in India at a low cost.
